Revolutionary Nanoparticle Cancer Vaccine Shows Stunning Results

Results from this phase showed 88% of mice rejected pancreatic tumors, 75% rejected breast tumors, and 69% rejected melanoma. All tumor-free mice also resisted further cancer spread.

The research, funded by the National Institutes of Health, was supported by UMass Amherst’s Biomedical Engineering Department, the Institute for Applied Life Sciences and UMass Chan Medical School. Findings were published Oct. 9 in Cell Reports Medicine.